EUVIMEDEUVIMED entdecken
ÄquivalenzstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study

Qinjiao Fu, Chunqi Huang, Yuan Yuan, Yu Wang, Bin Zhu, Yanzhu Liu, Fang Tian, Xiufeng Xu, Lei Yang, Yingying Xu, Ying Wang

Drugs in R&D · 2025

DOI: 10.1007/s40268-025-00519-4 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Drugs in R&D, 2025. Verfasst von Qinjiao Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Nitroglycerin, Vasodilator Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Nitroglycerin, a cornerstone therapy for acute angina pectoris, achieves rapid symptom relief through sublingual administration by bypassing hepatic first-pass metabolism. This study aimed to investigate the pharmacokinetics (PK), bioequivalence, and safety profiles between a test (T) formulation and a reference (R) formulation of nitroglycerin sublingual tablets in healthy volunteers (HVs). METHODS: In this single-center, randomized, open, single-dose, two-part formulations, four-cycle, two-sequence complete repeat crossover design, fasting-dose bioequivalence study, HVs (n = 36) were 1:1 divided into two groups (T-R-T-R and R-T-R-T) and received 0.6 mg of nitroglycerin sublingual with a 3 d washout. Venous blood was collected 3 h after each administration. Plasma levels of nitroglycerin were analyzed using a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) technique, and PK parameters were calculated using noncompartmental methods. RESULTS: For nitroglycerin, the bioequivalence between the test and reference formulations was assessed using the Reference-Scaled Average Bioequivalence (RSABE) method for the maximum plasma concentration (Cmax), area under the curve (AUC) from t = 0 to infinity (AUC0-∞) and AUC from t = 0 to the final measurable concentration (AUC0-t). Results showed that the least squares geometric mean ratios (T/R) of Cmax, AUC0-t, and AUC0-∞ for nitroglycerin (94.62%, 89.92%, and 89.44%, respectively) were in the range of 80.00-125.00%, and the upper limit of unilateral 95% confidence interval (CI) of Cmax, AUC0-t, and AUC0-∞ for nitroglycerin (-0.06, -0.03, and -0.03, respectively) were less than 0. Safety profiles were comparable between formulations, with no serious adverse events (AE) reported. CONCLUSIONS: The study confirmed bioequivalence between the test and reference formulations, demonstrating equivalent absorption rates (Cmax) and extents (AUC). Rapid therapeutic plasma levels were achieved via sublingual administration, aligning with nitroglycerin's clinical need for prompt angina relief. These findings, combined with favorable safety data, support the test formulation as a therapeutically equivalent alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroglycerinVasodilator AgentsAdultFemaleHumansMaleYoung AdultAdministration, SublingualArea Under CurveChinaChromatography, High Pressure LiquidCross-Over StudiesHealthy VolunteersTabletsTandem Mass SpectrometryTherapeutic EquivalencyEast Asian People

Substanzen

NitroglycerinTabletsVasodilator Agents

Autor:innen und Institutionen

  • School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, People's Republic of China.
  • Department of Clinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, West Lake University, Hangzhou, 310006, Zhejiang, People's Republic of China.
  • Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, Zhejiang, People's Republic of China.
  • Department Phase I Clinical Research Center, Hangzhou Red Cross Hospital, Hangzhou, 310005, Zhejiang, People's Republic of China.
  • Neoform Biopharmaceutical Co., Ltd, Shenzhen, 518000, Guangdong, People's Republic of China.
  • Department Phase I Clinical Research Center, Hangzhou Red Cross Hospital, Hangzhou, 310005, Zhejiang, People's Republic of China. xuyingying208@163.com.

Zitieren

APA

Fu, Q., Huang, C., Yuan, Y., Wang, Y., Zhu, B., Liu, Y., Tian, F., Xu, X., Yang, L., Xu, Y., & Wang, Y. (2025). Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study. Drugs in R&D. https://doi.org/10.1007/s40268-025-00519-4

Vancouver

Fu Q, Huang C, Yuan Y, Wang Y, Zhu B, Liu Y, et al. Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study. Drugs in R&D. 2025. doi:10.1007/s40268-025-00519-4

BibTeX
@article{Fu2025,
  author = {Fu, Qinjiao and Huang, Chunqi and Yuan, Yuan and Wang, Yu and Zhu, Bin and Liu, Yanzhu and Tian, Fang and Xu, Xiufeng and Yang, Lei and Xu, Yingying and Wang, Ying},
  title = {Assessment of Pharmacokinetics and Safety with Bioequivalence of the Nitroglycerin Sublingual Tablets of Two Formulations in Chinese Healthy Subjects: A Bioequivalence Study},
  journal = {Drugs in R&D},
  year = {2025},
  doi = {10.1007/s40268-025-00519-4}
}
Kostenlos starten →